Sign in
TerminatedPhase 1/2

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

Key facts

Who runs it
Korro Bio, Inc.
Where
Australia and New Zealand5 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
42 people enrolled
Started
13 Jan 2025
Ended
15 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • KRRO-110
Record updated
17 April 2026
Why it stopped
The study was terminated for business decision reasons.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Part A SAD cohort Inclusion Criteria (Healthy Volunteers)
  • Adult male or female participants, 18 to 65 years of age
  • Documented PiMM genotype
  • Participants who are willing to and able to provide signed written informed consent; PiZZ Genotype (Part A SAD and Part B MAD cohorts) Inclusion Criteria (PiZZ Genotype)
  • Adult male or female participants 18 to 70 years of age (inclusive)
  • Documented PiZZ genotype
  • Baseline blood total AAT level < 11 µM/L

Who cannot take part

  • Use of an experimental therapy except KRRO-110 within 6 months or 5 half-lives for the experimental therapy, whichever is greater
  • Use of conventionally dosed AAT augmentation therapy within 5 half-lives
  • History or current clinical evidence of hepatic disease
  • Evidence of active infection
  • History of medical condition(s), eg, advance cardiac disease, current or recent malignancy, organ transplantation, or other illness
  • Serology result indicative of any exposure (past or active) to hepatitis C, hepatitis B, or human immunodeficiency virus (HIV)
  • Respiratory or other acute illness within 8 weeks
  • History of FEV1 < 35%
  • History or current clinical evidence of advanced hepatic disease and/or pulmonary disease
  • Serology result consistent with exposure to HIV, or serology consistent with active hepatitis B or hepatitis C infection
  • Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
  • Body mass index (BMI) > 32 or < 18.5 kg/m2
  • Tobacco use of any kind within 6 months
  • Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
  • BMI > 32 or < 18.5 kg/m2 or weight > 90 kg
  • Tobacco use of any kind within 6 months

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

The 2 groups in the trial

  • Arm 1: KRRO-110 (Part A and Part B)Treatment being tested

    KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).

    Treatment: KRRO-110

  • Arm 2: Placebo (Part A only)Placebo, for comparison

    Placebo, IV administration

    Treatment: KRRO-110

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
Record updated
17 April 2026